Helus Pharma Inc. (HELP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 40-F for FY2025, filed Jul 1, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the HELP SEC filings page.
This page shows Helus Pharma Inc. (HELP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Helus Pharma Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Helus Pharma Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Helus Pharma Inc. reported a net loss of $78.7M while operations used $70.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Helus Pharma Inc. reported a net loss of $78.7M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Helus Pharma Inc. held $93.9M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Helus Pharma Inc.'s ROE was -47.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 20.9 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Helus Pharma Inc. invested $38.2M in research and development in fiscal year 2025. This represents an increase of 59.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
HELP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2540-F | FY2440-F | FY2340-F | FY2240-F | FY2140-F |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $0-100.0% | $687K |
| Cost of Revenue | N/A | N/A | N/A | $0-100.0% | $528K |
| Gross Profit | N/A | N/A | N/A | $0-100.0% | $159K |
| R&D Expenses | $38.2M+59.8% | $23.9M+26.8% | $18.8M+33.8% | $14.1M+436.7% | $2.6M |
| Interest Expense | $5K-17.6% | $6K | N/A | N/A | N/A |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Net Income | -$78.7Mn/m | -$57.7Mn/m | -$35.1Mn/m | -$54.2Mn/m | -$25.6M |
| EPS (Basic) | -$3.89 | -$6.95 | -$0.19n/m | -$0.32 | -$0.25 |
| EPS (Diluted) | N/A | N/A | -$0.19n/m | -$0.32 | -$0.25 |
Not reported in any period shown, so not listed: SG&A Expenses, Operating Income, EBITDA, Diluted Shares (Avg).
HELP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2540-F | FY2440-F | FY2340-F | FY2240-F | FY2140-F |
|---|---|---|---|---|---|
| Total Assets | $179.9M-19.4% | $223.1M+459.7% | $39.8M-40.8% | $67.3M-8.1% | $73.3M |
| Current Assets | $115.4M-28.5% | $161.4M+841.5% | $17.1M-63.3% | $46.8M-11.6% | $52.9M |
| Cash & Equivalents | $93.9M-39.2% | $154.4M+1155.1% | $12.3M-71.4% | $43.0M-15.6% | $50.9M |
| Accounts Receivable | $4.1M+23.8% | $3.3M+46.6% | $2.3M+33.9% | $1.7M+59.3% | $1.1M |
| Goodwill | $35.8M+2.1% | $35.1M+91.3% | $18.3M-0.1% | $18.3M-1.3% | $18.6M |
| Total Liabilities | $14.9M+99.8% | $7.5M+78.1% | $4.2M-33.9% | $6.3M+32.9% | $4.8M |
| Current Liabilities | $14.9M+99.8% | $7.5M+78.1% | $4.2M-33.9% | $6.3M+62.5% | $3.9M |
| Non-Current Liabilities | $0n/m | $0n/m | $0n/m | $0-100.0% | $870K |
| Total Equity | $165.0M-23.5% | $215.6M+504.6% | $35.7M-41.5% | $61.0M-10.9% | $68.5M |
| Retained Earnings | -$236.0Mn/m | -$167.1Mn/m | -$109.5Mn/m | -$80.6Mn/m | -$26.3M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Long-Term Debt.
HELP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2540-F | FY2440-F | FY2340-F | FY2240-F | FY2140-F |
|---|---|---|---|---|---|
| Operating Cash Flow | -$70.4Mn/m | -$50.9Mn/m | -$35.1Mn/m | -$36.2Mn/m | -$15.1M |
| Depreciation & Amortization | $330K+5.5% | $313K+68.7% | $186K | N/A | N/A |
| Capital Expenditures | N/A | $16K-85.2% | $105K+24.8% | $84K-21.7% | $107K |
| Free Cash Flow | N/A | -$50.9Mn/m | -$35.2Mn/m | -$36.3Mn/m | -$15.2M |
| Investing Cash Flow | -$1.4M-126.7% | $5.1Mn/m | -$2.4Mn/m | -$617Kn/m | -$946K |
| Financing Cash Flow | $14.0M-92.5% | $188.0M+1774.3% | $10.0M-65.0% | $28.7M-56.4% | $65.8M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
HELP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2540-F | FY2440-F | FY2340-F | FY2240-F | FY2140-F |
|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | 23.2% |
| Net Margin | N/A | N/A | N/A | N/A | -3729.2% |
| Return on Equity | -47.7%-20.9pp | -26.8%+71.7pp | -98.5%-9.7pp | -88.8%-51.4pp | -37.4% |
| Return on Assets | -43.8%-17.9pp | -25.9%+62.3pp | -88.1%-7.7pp | -80.5%-45.5pp | -35.0% |
| Current Ratio | 7.75-13.9x | 21.65+17.6x | 4.09-3.3x | 7.38-6.2x | 13.57 |
| Liabilities-to-Equity | 0.09+0.1x | 0.03-0.1x | 0.120.0x | 0.100.0x | 0.07 |
| Asset Turnover | N/A | N/A | N/A | 0.000.0x | 0.01 |
| FCF Margin | N/A | N/A | N/A | N/A | -2217.8% |
Not reported in any period shown, so not listed: Operating Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Where Helus Pharma Inc. Ranks
Frequently Asked Questions
Is Helus Pharma Inc. profitable?
No, Helus Pharma Inc. (HELP) reported a net loss of $78.7M in fiscal year 2025.
What is Helus Pharma Inc.'s return on equity (ROE)?
Helus Pharma Inc. (HELP) has a return on equity of -47.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Helus Pharma Inc.'s operating cash flow?
Helus Pharma Inc. (HELP) recorded an outflow of $70.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Helus Pharma Inc.'s total assets?
Helus Pharma Inc. (HELP) had $179.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Helus Pharma Inc. spend on research and development?
Helus Pharma Inc. (HELP) invested $38.2M in research and development during fiscal year 2025.
What is Helus Pharma Inc.'s current ratio?
Helus Pharma Inc. (HELP) had a current ratio of 7.75 as of fiscal year 2025, which is generally considered healthy.
What is Helus Pharma Inc.'s liabilities-to-equity ratio?
Helus Pharma Inc. (HELP) had a liabilities-to-equity ratio of 0.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Helus Pharma Inc.'s return on assets (ROA)?
Helus Pharma Inc. (HELP) had a return on assets of -43.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Helus Pharma Inc.'s P/E ratio?
Helus Pharma Inc. (HELP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $767.1M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Helus Pharma Inc.'s price-to-sales ratio?
Helus Pharma Inc. (HELP) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $767.1M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Helus Pharma Inc.'s Piotroski F-Score?
Helus Pharma Inc. (HELP) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Helus Pharma Inc.'s earnings high quality?
Helus Pharma Inc. (HELP) reported a net loss of $78.7M while operations used $70.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.